Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression
Rodolfo Myronn de Melo Rodrigues
Psychedelics. August 12, 2024 DOI: 10.61373/pp024c.0022 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Intervention | Psilocybin-assisted psychotherapy |
| Topics | Psilocybin Psychedelic-assisted therapy Depression |
| Keywords | Psychedelics Depression treatment Resistant depression Mental health Mental care Well-being Clinical research Groundbreaking research Innovative treatment Medical research New therapies Psilocybin-assisted psychotherapy Pap Psychedelic medicine |
| Key points | Psilocybin assisted psychotherapy shows promise for treating depression. |
Abstract
Depression is a global public health challenge that represents the world's largest cause of disability, especially in the context of traditional treatments. One potential solution being explored is psilocybin assisted psychotherapy (PAP) which shows promise for treating depression. A recent study by Rosenblat et al. explores the use of psilocybin in clinical mental care with promising results (1).